Alexion's pexelizumab trial does not reduce mortality

By Elaine Rigoli

Tampa, Fla., June 28 - Alexion Pharmaceuticals, Inc. reported preliminary results from the phase 3 APEX-AMI clinical trial with pexelizumab, showing that the drug did not achieve a statistically significant reduction in mortality at 30 days following primary percutaneous coronary intervention (PCI) or angioplasty.

The primary endpoint in the APEX-AMI trial is a reduction in mortality at 30 days following PCI.

Pexelizumab, a terminal complement inhibitor, is a monoclonal antibody fragment that inhibits complement-mediated tissue damage.

The phase 3 trial included about 5,700 patients and compared the safety and efficacy of pexelizumab against that of a placebo in reducing death in patients experiencing a heart attack who are treated with PCI.

Alexion expects that the trial results will be presented at an upcoming scientific meeting. The trial was conducted at more than 300 U.S. and international study sites.

Alexion is a biotechnology company based in Chesire, Conn.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.